TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24708726

Group type: EXPERIMENTAL
Intervention: Integrative Medicine (IM) intervention at UAIHC
Number of subjects: 500

Group type: COMPARATOR
Intervention: Matched control groups
Number of subjects: 500

Group type: COMPARATOR
Intervention: Self-report measures
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Fidelity data from clinic patients and personnel
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Qualitative study of 8 patients
Number of subjects: 500
Study: 24709691

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 457
Study: 24709811

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.15% for 8 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study: 24710133

Group type: EXPERIMENTAL
Intervention: Prednisone/prednisolone with salbutamol and cointerventions (ipratropium bromide)
Number of subjects: 1008
Study: 24710654

Group type: EXPERIMENTAL
Intervention: Continuous subhairline electroencephalographic (cEEG) monitoring
Number of subjects: 101
Study: 24710768

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy plus cetuximab (weekly cetuximab plus 3-week cycles of cisplatin/5-FU for up to 6 cycles)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy plus cetuximab
Number of subjects: 68
Study: 24710915

Group type: EXPERIMENTAL
Intervention: Diet emphasizing dietary pulse intake (median dose of 130 g/d)
Number of subjects: 1037

Group type: COMPARATOR
Intervention: Isocaloric diet without dietary pulses
Number of subjects: 1037
Study: 24711212

Group type: EXPERIMENTAL
Intervention: Bosutinib
Number of subjects: 288
Study: 24711230

Group type: EXPERIMENTAL
Intervention: Progression risk score based on biological markers (CD38, ZAP-70, IGHV mutational status)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Progression risk score applied to Rai 0 cases
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Cox multivariate analysis including Rai stage, absolute lymphocyte count, progression risk score, and β-2 microglobulin
Number of subjects: 468
Study: 24711549

Group type: EXPERIMENTAL
Intervention: Lapatinib (7,000 mg per day in twice-daily dosing)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lapatinib with ketoconazole (to increase exposure)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intermittent dosing of lapatinib
Number of subjects: 40
Study: 24711551

Group type: EXPERIMENTAL
Intervention: hu14.18K322A (60 mg/m(2) per day for 4 days)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: hu14.18K322A
Number of subjects: 38
Study: 24711599

Group type: EXPERIMENTAL
Intervention: Community-linked supervision approach
Number of subjects: 824

Group type: COMPARATOR
Intervention: Facility-only supervision approach
Number of subjects: 824
Study: 24712435

Group type: EXPERIMENTAL
Intervention: Ecallantide
Number of subjects: 521

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 521
Study: 24712447

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - four 5 minute cycles of upper limb ischemia/reperfusion
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (no RIPC)
Number of subjects: 35
Study: 24712564

Group type: EXPERIMENTAL
Intervention: Synthetic human GIP (20 ng · kg(-1) · min(-1))
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (saline 0.9% NaCl)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: GIP bolus in C57BL/6 mice
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Number of subjects: 92
Study: 24712976

Group type: EXPERIMENTAL
Intervention: TF-CBT
Number of subjects: 135

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 135
Study: 24713455

Group type: EXPERIMENTAL
Intervention: CHADS₂ score 1-2
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: CHADS₂ score ≥ 3
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: CHADS₂ score
Number of subjects: 297
Study: 24714268

Group type: EXPERIMENTAL
Intervention: Therapeutic endoscopy
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Blood product transfusions
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors administration
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Uncontrolled bleeding or rebleeding
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Second-look endoscopy
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Angiographic intervention
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Mortality during hospitalization
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Mortality during 30-day post-hospitalization period
Number of subjects: 201
Study: 24714488

Group type: EXPERIMENTAL
Intervention: High-grade rejection (≥3A)
Number of subjects: 48

Group type: COMPARATOR
Intervention: None/mild rejection (0, 1A/1B, or 2)
Number of subjects: 48
Study: 24714750

Group type: EXPERIMENTAL
Intervention: Ombrabulin (35 mg/m²) with docetaxel (75 mg/m²)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Ombrabulin (30 mg/m²) with docetaxel (100 mg/m²)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Ombrabulin (42 mg/m²) with docetaxel (75 mg/m²)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Ombrabulin (35 mg/m²) with docetaxel (100 mg/m²)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Ombrabulin (30 mg/m²) with docetaxel (75 mg/m²)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Ombrabulin (100 mg/m²) with docetaxel (100 mg/m²)
Number of subjects: 58
Study: 24714778

Group type: EXPERIMENTAL
Intervention: Cediranib 45 mg/day
Number of subjects: 34
Study: 24714806

Group type: EXPERIMENTAL
Intervention: Specific ceramide, phosphatidylcholine and phosphatidylethanolamine lipids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidylcholine and phosphatidylethanolamine lipids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LPC a C18:1 and PE ae C40:6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRP, TNF-α, resistin and MCP-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-8
Number of subjects: 0
Study: 24714973

Group type: EXPERIMENTAL
Intervention: Zalutumumab (weekly infusions, individually titrated to a grade 2 skin rash)
Number of subjects: 90
Study: 24715201

Group type: EXPERIMENTAL
Intervention: 3D movement correction method for CT brain perfusion (CTP) acquisition
Number of subjects: 35

Group type: COMPARATOR
Intervention: Original CTP data
Number of subjects: 35
Study: 24715548

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15-30 mg/day) for 8 weeks
Number of subjects: 34
Study: 24716469

Group type: EXPERIMENTAL
Intervention: GSK933776 1 mg/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GSK933776 3 mg/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GSK933776 6 mg/kg
Number of subjects: 18
Study: 24716542

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (260 mg/m² i.v. on day 1 of each 21-day cycle)
Number of subjects: 56
Study: 24716655

Group type: EXPERIMENTAL
Intervention: Florbetapir F 18 (amyloid imaging agent)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 18F-AV-133 (florbenazine, VMAT2 density marker)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Florbenazine binding in DLB patients
Number of subjects: 31
Study: 24717109

Group type: EXPERIMENTAL
Intervention: Ocaratuzumab 375 mg/m(2) weekly for 4 weeks
Number of subjects: 50
Study: 24717325

Group type: EXPERIMENTAL
Intervention: Presence of plaques in multi-detector computed tomography
Number of subjects: 0
Study: 24717340

Group type: EXPERIMENTAL
Intervention: Added sugars consumption
Number of subjects: 320

Group type: COMPARATOR
Intervention: Sodium intake
Number of subjects: 320

Group type: COMPARATOR
Intervention: Dietary fat intake
Number of subjects: 320
Study: 24717362

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25(OH)D) ≥ ∼26 μg/L (65.0 pmol/L)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor-1 (IGF-1)
Number of subjects: 239
Study: 24717379

Group type: EXPERIMENTAL
Intervention: Lithium in monotherapy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Prophylactic medication changed by psychiatrist
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Prophylactic medication stopped by patient
Number of subjects: 300

Group type: COMPARATOR
Intervention: General relapse data
Number of subjects: 300

Group type: COMPARATOR
Intervention: Relapse correlation with index episode
Number of subjects: 300
Study: 24717420

Group type: EXPERIMENTAL
Intervention: Obese group (n=92)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (n=49)
Number of subjects: 92
Study: 24717624

Group type: EXPERIMENTAL
Intervention: High-resolution CT classified as usual interstitial pneumonia
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: High-resolution CT classified as possible usual interstitial pneumonia
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: High-resolution CT classified as inconsistent with usual interstitial pneumonia
Number of subjects: 315
Study: 24717623

Group type: EXPERIMENTAL
Intervention: Lower respiratory consultations (infective and non-infective)
Number of subjects: 38859

Group type: EXPERIMENTAL
Intervention: Lower respiratory consultations with a course of antibiotics or oral steroids
Number of subjects: 38859

Group type: EXPERIMENTAL
Intervention: Chest radiography
Number of subjects: 38859

Group type: EXPERIMENTAL
Intervention: Age at diagnosis
Number of subjects: 38859

Group type: EXPERIMENTAL
Intervention: Yearly frequency of lower respiratory prescribing consultations
Number of subjects: 38859

Group type: EXPERIMENTAL
Intervention: Prevalence of comorbidities at COPD diagnosis
Number of subjects: 38859

Group type: EXPERIMENTAL
Intervention: Chest radiography and spirometry
Number of subjects: 38859
Study: 24718643

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 24719405

Group type: EXPERIMENTAL
Intervention: IL-2-diphtheria fusion protein (IL2DT)
Number of subjects: 57
Study: 24720836

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) rituximab
Number of subjects: 3

Group type: COMPARATOR
Intervention: Intravenous (IV) rituximab
Number of subjects: 3
Study: 24720900

Group type: EXPERIMENTAL
Intervention: Genetically modified dendritic cells in combination with Cytokine-Induced Killer Cell treatment (gmDCs-CIK)
Number of subjects: 28
Study: 24721145

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Low n-3 PUFA group
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Low n-3/n-6 PUFA group
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Low total PUFA group
Number of subjects: 676
Study: 24721422

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Second-line TNFi (Adalimumab)
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Second-line TNFi (Etanercept)
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Second-line TNFi (Infliximab)
Number of subjects: 706
Study: 24721691

Group type: EXPERIMENTAL
Intervention: Self-reported indicators of periodontal disease (PD)
Number of subjects: 15828

Group type: EXPERIMENTAL
Intervention: Tooth loss
Number of subjects: 15828

Group type: EXPERIMENTAL
Intervention: Gum bleeding
Number of subjects: 15828
Study: 24721800

Group type: EXPERIMENTAL
Intervention: Intravenous propranolol and atropine
Number of subjects: 73
Study: 24722180

Group type: EXPERIMENTAL
Intervention: High testosterone level (above median TL of 11.5 ng/dl), n=52
Number of subjects: 101

Group type: COMPARATOR
Intervention: Low testosterone level (below median TL of 11.5 ng/dl), n=49
Number of subjects: 101

Group type: COMPARATOR
Intervention: Presence of anaemia
Number of subjects: 101

Group type: COMPARATOR
Intervention: Patients with both anaemia and low testosterone
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: High testosterone level (above median TL of 11.5 ng/dl) receiving salvage hormonal therapy (SHT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Low testosterone level (below median TL of 11.5 ng/dl) receiving salvage hormonal therapy (SHT)
Number of subjects: 101
Study: 24722222

Group type: EXPERIMENTAL
Intervention: Adults younger than 55 years with severe burn injuries and inhalation injury
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Adults aged 55 years and older
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Patients younger than 17 years
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 541
Study: 24722322

Group type: EXPERIMENTAL
Intervention: Doppler assessment of respirophasic ΔVpeak-CA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pulse pressure variation (PPV)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of ΔVpeak-CA in patients with pulse pressure hypertension (≥ 60 mm Hg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of PPV in patients with pulse pressure hypertension (≥ 60 mm Hg)
Number of subjects: 40
Study: 24722393

Group type: EXPERIMENTAL
Intervention: Cocktail alone (session 1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cocktail with fluvoxamine and voriconazole (session 2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cocktail with quinidine (session 3)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cocktail after 7-day pretreatment with rifampicin (session 4)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Minimally invasive one- and three-point DBS-sampling methods
Number of subjects: 10
Study: 24723023

Group type: EXPERIMENTAL
Intervention: Clinical nomogram based on four independent factors (previous laparotomies, anatomical site of operation, presence of bowel fistula, laparotomy via pre-existing median scar)
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Inadvertent bowel injury during adhesiolysis
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Bowel resection required for enterotomies
Number of subjects: 715
Study: 24723284

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 319
Study: 24723428

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) for patients with comorbid GERD (n = 72)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS) for patients without GERD (n = 157)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Active medical therapy for GERD (n = 49)
Number of subjects: 229
Study: 24723493

Group type: EXPERIMENTAL
Intervention: Pentostatin, alemtuzumab, and low-dose high-frequency rituximab
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Low-dose rituximab
Number of subjects: 39
Study: 24723677

Group type: EXPERIMENTAL
Intervention: Low-dose plerixafor treatment
Number of subjects: 0
Study: 24725395

Group type: EXPERIMENTAL
Intervention: rHuIL-12 at doses of 2, 5, 10, 12, and 15 μg; 20 μg in the FIH study; 12 μg in the phase 1b expansion study.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 24725582

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 918

Group type: COMPARATOR
Intervention: Intubation/Surfactant
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 918
Study: 24725803

Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Human insulin (HI)
Number of subjects: 19

Group type: COMPARATOR
Intervention: BIAsp70
Number of subjects: 19

Group type: COMPARATOR
Intervention: BIAsp50
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: All insulin preparations
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bioactive IGF
Number of subjects: 19
Study: 24725832

Group type: EXPERIMENTAL
Intervention: Preoperative BNP levels
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Postoperative BNP levels
Number of subjects: 277
Study: 24725992

Group type: EXPERIMENTAL
Intervention: 3D culture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: miRNA mimics (hsa-miR-146b-5p and hsa-miR-99a)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Downregulated miRNAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hsa-miR-302a, hsa-miR-182, hsa-miR-7, hsa-miR-20a/b, hsa-miR-17
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hsa-miR-96
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hsa-miR-7 and hsa-miR-17
Number of subjects: 0
Study: 24726012

Group type: EXPERIMENTAL
Intervention: MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (MART-1 peptide vaccination without IMP321)
Number of subjects: 12
Study: 24726214

Group type: EXPERIMENTAL
Intervention: Atypical embryo phenotypes (AS, A1(cyt), AC, CC)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control embryos
Number of subjects: 67
Study: 24726226

Group type: EXPERIMENTAL
Intervention: LNG-IUS 13.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LNG-IUS 19.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: LNG-IUS 20 μg/24 h
Number of subjects: 0
Study: 24726248

Group type: EXPERIMENTAL
Intervention: Nutritional status and environmental factors (season)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Age, village, and time of visit
Number of subjects: 203
Study: 24726253

Group type: EXPERIMENTAL
Intervention: LA emptying fraction measurement
Number of subjects: 0
Study: 24726680

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg once daily for 7 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: HCTZ 25 mg once daily for 28 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg + HCTZ 25 mg once daily for 7 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Canagliflozin alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: HCTZ alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Canagliflozin + HCTZ
Number of subjects: 30
Study: 24727704

Group type: EXPERIMENTAL
Intervention: Preoperative NT-proBNP≥1028 ng litre(-1)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: EuroSCORE II
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: NT-proBNP≥1028 ng litre(-1) in intermediate-risk patients (EuroSCORE II 2.0-10.0)
Number of subjects: 365
Study: 24728273

Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ketogenic diet + Bevacizumab
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 20
Study: 24728331

Group type: EXPERIMENTAL
Intervention: Risk score based on four variables: tenderness of hand or foot joints, early morning stiffness ≥30 min, high-positive autoantibodies, and positive ultrasonographic power Doppler signal
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low risk (score 0)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Moderate risk (score 1-2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High risk (score ≥3)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adding shared epitope to risk score
Number of subjects: 100
Study: 24728332

Group type: EXPERIMENTAL
Intervention: Imaging findings from the Osteoarthritis Initiative (OAI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI findings on cartilage morphology, cartilage lesions and composition (T2), bone, meniscus, muscle and adipose tissue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Public access to clinical and image data from OAI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term observations from OAI
Number of subjects: 0
Study: 24728416

Group type: EXPERIMENTAL
Intervention: 5 cups per day of instant caffeinated coffee
Number of subjects: 32

Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 32

Group type: COMPARATOR
Intervention: Water
Number of subjects: 32
Study: 24729079

Group type: EXPERIMENTAL
Intervention: Intravitreal injections of ranibizumab
Number of subjects: 0
Study: 24729519

Group type: EXPERIMENTAL
Intervention: Breast milk adiponectin
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Breast milk leptin
Number of subjects: 118
Study: 24730732

Group type: EXPERIMENTAL
Intervention: HCV-infected patients
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: HIV/HCV-infected patients
Number of subjects: 461

Group type: COMPARATOR
Intervention: HIV infection
Number of subjects: 461

Group type: COMPARATOR
Intervention: Fib-4 score > 1.45
Number of subjects: 461

Group type: COMPARATOR
Intervention: Hypovitaminosis D
Number of subjects: 461

Group type: COMPARATOR
Intervention: HCV GT6
Number of subjects: 461
Study: 24731226

Group type: EXPERIMENTAL
Intervention: Community-based salt reduction intervention based on the Communication for Behavioural Impact framework, duration 6-12 months.
Number of subjects: 0
Study: 24731268

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 116
Study: 24731816

Group type: EXPERIMENTAL
Intervention: Two-dose schedule (Months 0 and 6)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three-dose schedule (Months 0, 1, and 6)
Number of subjects: 0
Study: 24732325

Group type: EXPERIMENTAL
Intervention: Low-dose non-adjuvanted intradermal (ID) vaccine
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Full-dose MF59-adjuvanted intramuscular (IM) vaccine
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Full-dose MF59-adjuvanted IM vaccine
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Low-dose non-adjuvanted ID vaccine
Number of subjects: 450
Study: 24733029

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 61
Study: 24733194

Group type: EXPERIMENTAL
Intervention: Virtual autopsy by multiphase PMCT angiography
Number of subjects: 143

Group type: COMPARATOR
Intervention: Medical autopsy
Number of subjects: 143
Study: 24733245

Group type: EXPERIMENTAL
Intervention: Ibuprofen (oral route, median dose of 10.0 mg/kg; range 3.4-11.4 mg/kg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ibuprofen (oral route)
Number of subjects: 28
Study: 24733463

Group type: EXPERIMENTAL
Intervention: Posaconazole i.v. 200 mg q.d.
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Posaconazole i.v. 300 mg q.d.
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 24733473

Group type: EXPERIMENTAL
Intervention: AVP-21D9 (anthrax monoclonal antibody)
Number of subjects: 0